Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 172
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMG 172 is an antibody-drug conjugate (ADC) developed by Amgen for the treatment of cancer, specifically targeting relapsed or refractory clear cell renal cell carcinoma (ccRCC). It consists of a human IgG1 monoclonal antibody directed against CD27L (also known as CD70 antigen), conjugated via a non-cleavable linker to the cytotoxic agent maytansinoid DM1. The mechanism of action involves binding to CD27L on tumor cells, internalization of the ADC, and subsequent release of DM1 inside the cell, leading to microtubule inhibition and cell death. Clinical studies have shown that AMG 172 has a favorable pharmacokinetic profile but limited antitumor activity in ccRCC patients[1][2][3][7].
- Other names
- anti-CD27L antibody-drug conjugateanti-CD-27L antibody-drug conjugateanti-CD 27L antibody-drug conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on AMG 172.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 172.